Merck, 112251-1MG, α1-Acid Glycoprotein, Human Plasma

General description
Native α₁-acid glycoprotein from human plasma. Glycoprotein used for the study of the structure of oligosaccharide units. Consists of 40 - 45% carbohydrate. Present in human plasma at concentrations of 55 - 140 mg/100 ml. Clinically,α₁-AG is an acute-phase reactant that, together with haptoglobin, indicates acute inflammation. Selectively suppresses the augmentation of NK cell activity by IFN-α and IFN-γ. Theα₁-AG:α₁-antitrypsin ratio is useful in diagnosis of liver disease. A sialic acid-deficientα₁-AG has been observed in serum or urine of patients with Hodgkin’s disease, psoriatic arthritis, diabetes, and chronic myeloid leukemia. Sialic acid-deficientα₁-AG has an affinity for vitamin B₁₂.
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for to 3 months at (-20°C).
Prepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
Other Notes
Aso, H., et al. 1999. Inflammation 23, 117.
Schmid, K., et al. 1973. Biochemistry 12, 2711.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Toxicity: Standard Handling (A)